Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-08-12 09:09:27 - browse：4

Purple AML cells in blood flow — coverage from STAT — Acute myeloid leukemia cells amid blood flow. Adobe

The Food and Drug Administration issued a change to the warning label for Legend Biotech and Janssen’s myeloma CAR-T, Carvykti or cilta-cel, adding that some secondary blood cancers have occurred following treatment for multiple myeloma with the cell therapy.

While the label means that physicians will have to have a conversation about secondary malignancies occurring after Carvykti treatment, oncologists and CAR-T experts said the label update won’t change anything about the use of Carvykti.

“I do not believe this particular change will have any bearing on patient care,” said Saad Usmani, a myeloma physician and cell therapist at Memorial Sloan Kettering who has also studied Carvykti. That’s partly because physicians already discuss the risk of second cancers due to other cancer therapies including radiation, some targeted therapies, and some chemotherapies, which are necessary in the use of CAR-T. “We do have secondary primary malignancy discussions with patients in the context of transplant and will have to do for CAR-T as well,” Usmani said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Patient advocates sound warning on FDA proposal on salt intake

WSS

Medicare explains how it will choose drugs for negotiation

NYU Langone launches private ChatGPT for its health care data

Baltimore teen accused of firing into crowd during block party mass shooting

ActiGraph execs on goal of drug approvals with digital endpoints

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Medicare explains how it will choose drugs for negotiation

knowledge

Wikipedia

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What do new weight loss drugs mean for bariatric surgery?

United colonoscopy coverage change 'may cost lives,' doctors say

ProMED sees offers of support, but its future remains unclear

Hollywood unions extend contract negotiations for actors

Psilocybin's anti

Apple is now the first public company to be valued at $3 trillion

2024 GOP presidential candidates spar over abortion in debate

Bright Health sells Medicare Advantage business to Molina

How to make Best Hospitals ratings actually useful for patients

knowledge

FDA approves first treatment for ultra

Clinical trials must include more disabled people

ActiGraph execs on goal of drug approvals with digital endpoints

ActiGraph execs on goal of drug approvals with digital endpoints

Why more medical students aren't specializing in primary care

Baltimore teen accused of firing into crowd during block party mass shooting

leisure time

focus

hotspot

focus